Navigation Links
Breast Cancer Patients Take DNA Test to Determine Best Treatment
Date:10/30/2008

SEATTLE, Oct. 30 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment. According to the National Foundation for Cancer Research (NFCR), this failure rate can be reduced to less than ten percent, saving 20,000 lives each year, by having patients take a simple DNA test and properly managing their medications.

Recent research shows that tamoxifen has to be activated into endoxifen by the liver enzyme CYP2D6. Endoxifen is the medicine that prevents the recurrence of estrogen receptive positive cancers.

About ten percent of breast cancer patients prescribed tamoxifen are missing CYP2D6 because of their DNA, and will fail tamoxifen treatment. "Patients want to know that tamoxifen will definitely benefit them, before committing to take it for five years. DNA testing offers them the reassurance that their tamoxifen is effective," stated Dr. Michael Benjamin, oncologist and editor of the medical news website, InteractMD.com

Breast cancer patients can also fail tamoxifen treatment by unknowingly taking other prescription drugs, herbals preparations, or over-the-counter medicines that interfere with CYP2D6 activity. Many classes of drugs, including anti-depressants, prevent CYP2D6 from converting tamoxifen into endoxifen. That's why Genelex includes password-protected access to their GeneMedRx software program with each test. Patients enter all of the drugs they take and produce a report to learn if any of the drugs they take might be defeating their endoxifen treatment.

"Patients and physicians need to be aware that DNA testing for tamoxifen effectiveness is available now. There is typically a 10-year gap between research and application in the clinical setting. We need to shorten that time when people's lives are at stake -- as they are with tamoxifen," stated Genelex founder and CEO Howard Coleman.

For more information about the CYP2D6 DNA test, visit Genelex at http://www.HealthandDNA.com, or call (800) 532-3080. Genelex donates a portion of all tests purchased to the National Foundation for Cancer Research.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Howard Coleman

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=44528


'/>"/>
SOURCE Genelex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
7. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
8. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
11. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... 13, 2017 , ... FireflySci has been busy rolling out ... diverse customer base. The latest entry in this field is a series of ... Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, 10x2 and 10x4 ...
(Date:1/12/2017)... , ... January 12, 2017 ... ... devices with short response times capable of performing routine electrochemical biosensing has ... screen-printed electrodes provide fast, sensitive detection and quantification of various analytes in ...
(Date:1/12/2017)... Jan. 12, 2017   Protein Sciences Corporation ... of Flublok Influenza Vaccine ®, announced today ... had good safety results and induced strong neutralizing ... The product is expected to advance into human ... addition, the Institute of Technology in Immunobiologicals of ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial data ... the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 ... of these heavily pretreated patients saw clinical benefit from the drug, with at ...
Breaking Biology Technology:
(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/22/2016)... , December 22, 2016 SuperCom ... of secure solutions for the e-Government, Public Safety, HealthCare, and Finance ... of SuperCom, has been selected to implement and deploy a community-based ... Northern California , further expanding its presence in ... This ...
Breaking Biology News(10 mins):